Company research
Xilio Therapeutics, Inc.
CIK 1840233Updated Sep 27, 2026
SecurityXLO · NASDAQ · equity
XLO price & chart
Loading TradingView…
NASDAQ:XLO on TradingView ↗About the company
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
In the news
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
SCHEDULE 13G/A filing
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 154,685,000Source | 71,075,000Source | 60,926,000Source | 139,165,000Source |
| Property, Plant and Equipment, NetUSD | 3,892,000Source | 4,472,000Source | 5,942,000Source | 7,255,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 137,531,000Source | 55,291,000Source | 44,704,000Source | 120,385,000Source |
| Assets, CurrentUSD | 145,027,000Source | 60,234,000Source | 48,127,000Source | 124,496,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,496,000Source | 4,943,000Source | 3,423,000Source | 4,111,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,959,000Source | 4,587,000Source | 5,125,000Source | 5,585,000Source |
| Other Assets, NoncurrentUSD | — | — | 145,000Source | 267,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 119,412,000Source | 53,477,000Source | 24,099,000Source | 33,518,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | — | 5,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 454,062,000Source | 401,346,000Source | 362,336,000Source | 354,752,000Source |
| Retained Earnings (Accumulated Deficit)USD | -418,789,000Source | -383,753,000Source | -325,512,000Source | -249,108,000Source |
| Stockholders' Equity Attributable to ParentUSD | 35,273,000Source | 17,598,000Source | 36,827,000Source | 105,647,000Source |
| Liabilities and EquityUSD | 154,685,000Source | 71,075,000Source | 60,926,000Source | 139,165,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 56,273,000Source | 27,261,000Source | 15,957,000Source | 21,119,000Source |
| Operating Lease, Liability, CurrentUSD | 1,343,000Source | 1,188,000Source | 1,047,000Source | 918,000Source |
| Accounts Payable, CurrentUSD | 3,168,000Source | 2,574,000Source | 1,050,000Source | 3,125,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,611,000Source | 6,954,000Source | 8,142,000Source | 9,189,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 45,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 11,739,000Source | 9,981,000Source | 10,497,000Source | 10,327,000Source |
| Deferred Revenue, CurrentUSD | 40,023,000Source | 13,518,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 20,635,000Source | 19,262,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,541,000Source | 1,644,000Source | 1,900,000Source | 1,847,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,939,000Source | 6,434,000Source | 7,382,000Source | 8,424,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 5,000,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 152,000Source | 1,526,000Source | -2,063,000Source | 485,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,992,000Source | -18,378,000Source | -68,620,000Source | -75,723,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -518,000Source | -36,000Source | -486,000Source | -1,867,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 518,000Source | 36,000Source | 486,000Source | 1,867,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 87,775,000Source | 29,196,000Source | -6,550,000Source | -69,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 82,265,000Source | 10,782,000Source | -75,656,000Source | -77,659,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 139,338,000Source | 57,073,000Source | 46,291,000Source | 121,947,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 62,000Source | 573,000Source | 555,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,939,000Source | 6,434,000Source | 7,382,000Source | 8,424,000Source |
| DepreciationUSD | 1,500,000Source | 1,600,000Source | 1,800,000Source | 1,700,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | -3,000Source | -3,000Source | -1,000Source |
| General and Administrative ExpenseUSD | 29,709,000Source | 24,778,000Source | 26,997,000Source | 29,948,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Nonoperating Income (Expense)USD | 6,946,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Operating ExpensesUSD | 85,748,000Source | 66,926,000Source | 79,133,000Source | 89,149,000Source |
| Other Nonoperating Income (Expense)USD | 1,101,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Proceeds from Stock Options ExercisedUSD | 10,000Source | 5,000Source | 8,000Source | 16,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 43,766,000Source | 6,344,000Source | — | — |
| Operating Income (Loss)USD | -41,982,000Source | -60,582,000Source | -79,133,000Source | -89,149,000Source |
| Other Nonoperating Income (Expense)USD | 1,101,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -35,036,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Earnings Per Share, BasicUSD per share | -4.19Source | -1.09Source | -2.78Source | -3.22Source |
| Earnings Per Share, DilutedUSD per share | -4.19Source | -1.09Source | -2.78Source | -3.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,359,109Source | 53,511,424Source | 27,496,107Source | 27,392,087Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 29,709,000Source | 24,778,000Source | 26,997,000Source | 29,948,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -35,036,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 6,946,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Operating ExpensesUSD | 85,748,000Source | 66,926,000Source | 79,133,000Source | 89,149,000Source |
| Research and Development ExpenseUSD | 56,039,000Source | 41,211,000Source | 52,136,000Source | 59,201,000Source |
Filing attachments
xlo-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the…
Read attachment ↗xlo-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first…
Read attachment ↗xlo-ex99_1.htm · 8-K · 2026-03-23
EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential f…
Read attachment ↗